Published in J Clin Oncol on February 01, 2000
Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342. Breast Cancer Res (2006) 1.69
Progression-free survival as a surrogate endpoint in advanced breast cancer. Int J Technol Assess Health Care (2008) 1.16
A systematic review of taxane-containing regimens for metastatic breast cancer. Br J Cancer (2005) 1.15
(-)-Epigallocatechin gallate sensitizes breast cancer cells to paclitaxel in a murine model of breast carcinoma. Breast Cancer Res (2010) 0.98
Inhibition of RelB by 1,25-dihydroxyvitamin D3 promotes sensitivity of breast cancer cells to radiation. J Cell Physiol (2009) 0.94
A process for assessing the feasibility of a network meta-analysis: a case study of everolimus in combination with hormonal therapy versus chemotherapy for advanced breast cancer. BMC Med (2014) 0.94
Novel free paclitaxel-loaded poly(L-γ-glutamylglutamine)-paclitaxel nanoparticles. Int J Nanomedicine (2011) 0.92
Combination chemotherapy with paclitaxel, cisplatin and fluorouracil for patients with advanced and metastatic gastric or esophagogastric junction adenocarcinoma: a multicenter prospective study. Chin J Cancer Res (2012) 0.91
US Food and Drug Administration approval overview in metastatic breast cancer. J Clin Oncol (2012) 0.89
Phase I-II study of docetaxel and ifosfamide combination in patients with anthracycline pretreated advanced breast cancer. Br J Cancer (2003) 0.88
CDK5RAP2 is required for spindle checkpoint function. Cell Cycle (2009) 0.88
Phase II study of capecitabine in combination with paclitaxel in patients with anthracycline-pretreated advanced/metastatic breast cancer. Br J Cancer (2004) 0.88
Phase II study of CT-2103 as first- or second-line chemotherapy in patients with metastatic breast cancer: unexpected incidence of hypersensitivity reactions. Invest New Drugs (2007) 0.87
Tyrosine-phosphorylated caveolin-1 (Tyr-14) increases sensitivity to paclitaxel by inhibiting BCL2 and BCLxL proteins via c-Jun N-terminal kinase (JNK). J Biol Chem (2012) 0.86
Modeling the relationship between progression-free survival and overall survival: the phase II/III trial. Clin Cancer Res (2013) 0.86
Clinically relevant anticancer polymer Paclitaxel therapeutics. Cancers (Basel) (2010) 0.84
Optimal use of taxanes in metastatic breast cancer. Curr Oncol (2009) 0.83
Metronomic chemotherapy for metastatic breast cancer to prolong time to treatment failure to 12 months or more. Mol Clin Oncol (2012) 0.83
Cost-effectiveness of lapatinib plus letrozole in her2-positive, hormone receptor-positive metastatic breast cancer in Canada. Curr Oncol (2013) 0.82
Docetaxel versus docetaxel alternating with gemcitabine as treatments of advanced breast cancer: final analysis of a randomised trial. Ann Oncol (2009) 0.81
Generation and functional assessment of 3D multicellular spheroids in droplet based microfluidics platform. Lab Chip (2016) 0.81
Styrene maleic acid micelles as a nanocarrier system for oral anticancer drug delivery - dual uptake through enterocytes and M-cells. Int J Nanomedicine (2015) 0.80
Factors responsible for long-term survival in metastatic breast cancer. World J Surg Oncol (2014) 0.80
A Phase II trial of the combination of vinorelbine and capecitabine as second-line treatment in metastatic breast cancer previously treated with taxanes and/or anthracyclines. J Cancer Res Clin Oncol (2010) 0.80
Phase II study of gemcitabine in combination with vinorelbine versus gemcitabine followed by vinorelbine for metastatic breast cancer. Invest New Drugs (2009) 0.78
Weekly docetaxel in the treatment of metastatic breast cancer. Ther Clin Risk Manag (2008) 0.78
Surgical management of breast cancer liver metastases. HPB (Oxford) (2011) 0.78
Loss of FBXW7 and accumulation of MCL1 and PLK1 promote paclitaxel resistance in breast cancer. Oncotarget (2016) 0.77
Double high-dose chemotherapy with adriamycin, paclitaxel, cyclophosphamide, and thiotepa followed by autologous peripheral blood stem cell transplantation in women with metastatic breast cancer. J Cancer Res Clin Oncol (2003) 0.77
Downregulation of histone H2A and H2B pathways is associated with anthracycline sensitivity in breast cancer. Breast Cancer Res (2016) 0.76
Nab-paclitaxel, docetaxel, or solvent-based paclitaxel in metastatic breast cancer: a cost-utility analysis from a Chinese health care perspective. Clinicoecon Outcomes Res (2015) 0.76
First line targeted therapies in breast cancer: focus on bevacizumab. Biologics (2007) 0.76
Salvage therapy of pretreated advanced breast cancer with bevacizumab and paclitaxel every two weeks: a retrospective case review study. BMC Cancer (2009) 0.76
Noninvasive bioluminescence imaging of the dynamics of sanguinarine induced apoptosis via activation of reactive oxygen species. Oncotarget (2016) 0.75
Extraction protocol and mass spectrometry method for quantification of doxorubicin released locally from prodrugs in tumor tissue. J Mass Spectrom (2013) 0.75
Indication of metronomic chemotherapy for metastatic breast cancer: Clinical outcomes and responsive subtypes. Mol Clin Oncol (2016) 0.75
Predictive and prognostic values of BubR1 and synuclein-gamma expression in breast cancer. Int J Clin Exp Pathol (2015) 0.75
New approaches in the management of advanced breast cancer - role of combination treatment with liposomal doxorubicin. Breast Cancer (Dove Med Press) (2009) 0.75
Systematic review and network meta-analysis comparing palbociclib with chemotherapy agents for the treatment of postmenopausal women with HR-positive and HER2-negative advanced/metastatic breast cancer. Breast Cancer Res Treat (2017) 0.75
Docetaxel-ifosfamide combination in patients with HER2-non-overexpressing advanced breast cancer failing prior anthracyclines. Invest New Drugs (2007) 0.75
Purification and partial characterization of the major outer membrane protein of Chlamydia trachomatis. Infect Immun (1981) 18.13
Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med (2013) 13.90
Chlamydial infections (third of three parts). N Engl J Med (1978) 9.21
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet (2011) 8.24
Diagnosis of Chlamydia trachomatis genitourinary infection in women by ligase chain reaction assay of urine. Lancet (1995) 7.46
Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet (2001) 6.24
Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst (1998) 6.06
Chlamydial infections (first of three parts). N Engl J Med (1978) 5.79
Chlamydiae. Annu Rev Microbiol (1980) 5.47
Cathepsin-D in primary breast cancer: prognostic evaluation involving 2810 patients. Br J Cancer (1999) 5.47
Role of disulfide bonding in outer membrane structure and permeability in Chlamydia trachomatis. Infect Immun (1984) 5.00
Multicenter evaluation of the BDProbeTec ET System for detection of Chlamydia trachomatis and Neisseria gonorrhoeae in urine specimens, female endocervical swabs, and male urethral swabs. J Clin Microbiol (2001) 4.92
Antigenic analysis of the major outer membrane protein of Chlamydia spp. Infect Immun (1982) 4.82
Are chlamydial infections the most prevalent venereal disease? JAMA (1975) 4.79
Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer. Cancer Res (2000) 4.66
Severe endemic trachoma in Tunisia. Br J Ophthalmol (1976) 4.35
Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med (2001) 4.13
Chlamydial infections. Annu Rev Med (1981) 3.94
Diagnosis of Chlamydia trachomatis urethral infection in symptomatic and asymptomatic men by testing first-void urine in a ligase chain reaction assay. J Infect Dis (1994) 3.93
Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial. Lancet (2005) 3.75
BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients. Nat Genet (1997) 3.68
Rapid detection of BRCA1 mutations by the protein truncation test. Nat Genet (1995) 3.61
Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol (1997) 3.61
Screening for chlamydial infections in women attending family planning clinics. West J Med (1983) 3.51
Performance of the APTIMA Combo 2 assay for detection of Chlamydia trachomatis and Neisseria gonorrhoeae in female urine and endocervical swab specimens. J Clin Microbiol (2003) 3.50
Multicenter evaluation of the AMPLICOR and automated COBAS AMPLICOR CT/NG tests for detection of Chlamydia trachomatis. J Clin Microbiol (2000) 3.44
Chlamydial infections (second of three parts). N Engl J Med (1978) 3.40
Artesunate reduces but does not prevent posttreatment transmission of Plasmodium falciparum to Anopheles gambiae. J Infect Dis (2001) 3.36
Persistent infection with Chlamydia pneumoniae following acute respiratory illness. Clin Infect Dis (1992) 3.30
Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet (1998) 3.28
Failure of serology in diagnosing chlamydial infections of the female genital tract. J Clin Microbiol (1979) 3.27
Pneumonia due to Chlamydia trachomatis in the immunocompromised (nude) mouse. J Infect Dis (1981) 3.19
The 7.5-kb plasmid present in Chlamydia trachomatis is not essential for the growth of this microorganism. Plasmid (1990) 3.08
Prevalence of urethral Chlamydia trachomatis and Neisseria gonorrhoeae among asymptomatic, sexually active adolescent boys. J Infect Dis (1987) 3.02
The association of Chlamydia pneumoniae infection and reactive airway disease in children. Arch Pediatr Adolesc Med (1994) 2.92
The association between Chlamydia trachomatis and ectopic pregnancy. A matched-pair, case-control study. JAMA (1990) 2.91
Urinary leukocyte esterase screening test for asymptomatic chlamydial and gonococcal infections in males. JAMA (1989) 2.87
Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation. Lancet (2000) 2.84
Immunodiagnosis of sexually transmitted disease. Yale J Biol Med (1986) 2.82
The venereal nature of inclusion conjunctivitis. Am J Epidemiol (1967) 2.80
Comparison of monoclonal antibody staining and culture in diagnosing cervical chlamydial infection. J Clin Microbiol (1986) 2.80
Multicenter evaluation of AMPLICOR and automated COBAS AMPLICOR CT/NG tests for Neisseria gonorrhoeae. J Clin Microbiol (2000) 2.80
Prospective study of chlamydial infection in neonates. Lancet (1979) 2.80
Nonculture tests for genital tract chlamydial infection. What does the package insert mean, and will it mean the same thing tomorrow? Sex Transm Dis (1992) 2.80
The role of antibody in host defense against the agent of mouse pneumonitis. J Infect Dis (1982) 2.78
Lymphogranuloma venereum. II. Characterization of some recently isolated strains. J Bacteriol (1969) 2.78
Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet (2015) 2.70
Rapid diagnosis of sexually transmitted diseases--speed has a price. Diagn Microbiol Infect Dis (1986) 2.69
Integrating a modern knowledge-based system architecture with a legacy VA database: the ATHENA and EON projects at Stanford. Proc AMIA Symp (1999) 2.68
Latrine ownership as a protective factor in inflammatory trachoma in Egypt. Br J Ophthalmol (1991) 2.67
Topical tetracycline and rifampicin therapy of endemic trachoma in Tunisia. Am J Ophthalmol (1975) 2.66
Confirmatory assay increases specificity of the chlamydiazyme test for Chlamydia trachomatis infection of the cervix. J Clin Microbiol (1990) 2.65
Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. Ann Oncol (2010) 2.64
Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study. J Natl Cancer Inst (2000) 2.56
A role in vivo for tumor necrosis factor alpha in host defense against Chlamydia trachomatis. Infect Immun (1990) 2.55
Relative resistance to erythromycin in Chlamydia trachomatis. Antimicrob Agents Chemother (1980) 2.55
The current and future role of the medical oncologist in the professional care for cancer patients: a position paper by the European Society for Medical Oncology (ESMO). Ann Oncol (2013) 2.53
Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2. Ann Oncol (2014) 2.50
Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer (2005) 2.49
The long-term reproductive health consequences of female genital cutting in rural Gambia: a community-based survey. Trop Med Int Health (2001) 2.45
Infection with Chlamydia pneumoniae in Brooklyn. J Infect Dis (1991) 2.35
Pathogenesis of trachoma: the stimulus for inflammation. J Immunol (1987) 2.34
Role in vivo for gamma interferon in control of pneumonia caused by Chlamydia trachomatis in mice. Infect Immun (1988) 2.30
Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J Clin Oncol (1997) 2.29
Cellular immunity to the mouse pneumonitis agent. J Infect Dis (1984) 2.28
Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk. J Clin Oncol (2001) 2.25
Southern Ocean frontal structure and sea-ice formation rates revealed by elephant seals. Proc Natl Acad Sci U S A (2008) 2.24
Comparison of the major outer membrane protein variant sequence regions of B/Ba isolates: a molecular epidemiologic approach to Chlamydia trachomatis infections. J Infect Dis (1992) 2.21
Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol (2001) 2.21
Inhibition of antichlamydial IgM antibody by IgG antibody in immunofluorescence tests. J Immunol (1972) 2.20
Questioning specialists' attitudes to breast cancer follow-up in primary care. Ann Oncol (2007) 2.19
Isolation of bedsoniae from the joints of patients with Reiter's syndrome. Proc Soc Exp Biol Med (1966) 2.17
An animal model of trachoma II. The importance of repeated reinfection. Invest Ophthalmol Vis Sci (1982) 2.16
The burden of reproductive-organ disease in rural women in The Gambia, West Africa. Lancet (2001) 2.16
Major outer membrane protein variants of Chlamydia trachomatis are associated with severe upper genital tract infections and histopathology in San Francisco. J Infect Dis (1995) 2.12
Why we need a program for the control of Chlamydia trachomatis. N Engl J Med (1989) 2.12
Evaluation of urine-based screening strategies to detect Chlamydia trachomatis among sexually active asymptomatic young males. JAMA (1993) 2.12
Failure to detect Chlamydia pneumoniae in coronary atheromas of patients undergoing atherectomy. J Infect Dis (1996) 2.12
Chlamydia trachomatis: important relationships to race, contraception, lower genital tract infection, and Papanicolaou smear. J Pediatr (1984) 2.11
Chlamydia trachomatis infection and pregnancy outcome. Am J Obstet Gynecol (1987) 2.11
Plaque formation by Chlamydia in L cells. Infect Immun (1970) 2.09
A seroepidemiologic study of Chlamydia pneumoniae in Rhode Island. Evidence of serologic cross-reactivity. Chest (1993) 2.09
The intracellular life of Chlamydia. Curr Top Microbiol Immunol (1988) 2.09
The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res (2000) 2.09
Multiple-antigen slide test for detection of immunoglobulin M antibodies in newborn and infant sera by immunofluorescence. J Clin Microbiol (1981) 2.07
Pomegranate juice consumption reduces oxidative stress, atherogenic modifications to LDL, and platelet aggregation: studies in humans and in atherosclerotic apolipoprotein E-deficient mice. Am J Clin Nutr (2000) 2.07
Prospective study of perinatal transmission of Chlamydia trachomatis. JAMA (1986) 2.06
Factors associated with surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer: results from the NeoALTTO phase III trial. Ann Oncol (2013) 2.06
NIMH/APPC workgroup on behavioral and biological outcomes in HIV/STD prevention studies: a position statement. Sex Transm Dis (2000) 2.05
Enzyme immunoassay for diagnosis of gonorrhea. J Clin Microbiol (1984) 2.03
Differential human serologic response to two 60,000 molecular weight Chlamydia trachomatis antigens. J Infect Dis (1990) 2.02
Evaluation of nucleic acid amplification tests as reference tests for Chlamydia trachomatis infections in asymptomatic men. J Clin Microbiol (2000) 2.02
Successful re-treatment with taxol after major hypersensitivity reactions. J Clin Oncol (1993) 2.00
Chlamydia trachomatis-induced salpingitis in mice. J Infect Dis (1983) 1.99
Survival in hereditary breast cancer associated with germline mutations of BRCA2. J Clin Oncol (1999) 1.99
Pneumonitis following inclusion blennorrhea. J Pediatr (1975) 1.95
Human feeder layers for human embryonic stem cells. Biol Reprod (2003) 1.94